EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma

Michael L Wang iD, Wojciech Jurczak, Pier Luigi Zinzani iD, Toby A Eyre iD, Chan Y Cheah iD, Chaitra S Ujjani, Youngil Koh iD, Koji Izutsu iD, James N Gerson, Ian Flinn iD, Benoit Tessoulin iD, Alvaro J Alencar iD und 25 weitere

Journal of Clinical Oncology · 20.08.2023 · 41 (24) · 3988-3997

DOI: 10.1200/jco.23.00562 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.08.2023. Verfasst von Michael L Wang und 36 weiteren Autor:innen. Beteiligte Einrichtung: MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Lymphoma, Mantle-Cell. Die Arbeit wurde bisher 126-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Pirtobrutinib is a highly selective, noncovalent (reversible) Bruton tyrosine kinase inhibitor (BTKi). We report the safety and efficacy of pirtobrutinib in patients with covalent Bruton tyrosine kinase inhibitor (cBTKi) pretreated mantle-cell lymphoma (MCL), a population with poor prognosis. METHODS Patients with cBTKi pretreated relapsed/refractory (R/R) MCL received pirtobrutinib monotherapy in a multicenter phase I/II trial (BRUIN; ClinicalTrials.gov identifier: NCT03740529 ). Efficacy was assessed in the first 90 consecutively enrolled patients who met criteria for inclusion in the primary efficacy cohort. The primary end point was overall response rate (ORR). Secondary end points included duration of response (DOR) and safety. RESULTS The median patient age was 70 years (range, 46-87), the median prior lines of therapy was 3 (range, 1-8), 82.2% had discontinued a prior cBTKi because of disease progression, and 77.8% had intermediate- or high-risk simplified MCL International Prognostic Index score. The ORR was 57.8% (95% CI, 46.9 to 68.1), including 20.0% complete responses (n = 18). At a median follow-up of 12 months, the median DOR was 21.6 months (95% CI, 7.5 to not reached). The 6- and 12-month estimated DOR rates were 73.6% and 57.1%, respectively. In the MCL safety cohort (n = 164), the most common treatment-emergent adverse events (TEAEs) were fatigue (29.9%), diarrhea (21.3%), and dyspnea (16.5%). Grade ≥3 TEAEs of hemorrhage (3.7%) and atrial fibrillation/flutter (1.2%) were less common. Only 3% of patients discontinued pirtobrutinib because of a treatment-related adverse event. CONCLUSION Pirtobrutinib is a first-in-class novel noncovalent (reversible) BTKi and the first BTKi of any kind to demonstrate durable efficacy after prior cBTKi therapy in heavily pretreated R/R MCL. Pirtobrutinib was well tolerated with low rates of treatment discontinuation because of toxicity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Mantle-CellAdultHumansMiddle AgedAgedAged, 80 and overTyrosine Kinase InhibitorsNeoplasm Recurrence, LocalProtein Kinase InhibitorsPyrazoles

Substanzen

Tyrosine Kinase InhibitorsProtein Kinase InhibitorspirtobrutinibPyrazoles

Autor:innen und Institutionen

  • MD Anderson Cancer Center, Houston, TX.
  • Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland.
  • IRCCS Azienda Ospedaliero-Universitaria di Bologna Istituto di Ematologia "Seràgnoli," Bologna, Italy.
  • Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università di Bologna, Bologna, Italy.
  • Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, Oxford, United Kingdom.
  • Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, WA, Australia.

ORCID-Profile: Michael L Wang, Pier Luigi Zinzani, Toby A Eyre, Chan Y Cheah, Youngil Koh, Koji Izutsu, Ian Flinn, Benoit Tessoulin, Alvaro J Alencar, Shuo Ma, David Lewis, Ewa Lech-Maranda, Joanna Rhodes, Krish Patel, Nicole Lamanna, Yucai Wang, Constantine S Tam, Talha Munir, Anita Kumar, Timothy S Fenske, John F Seymour, Andrew D Zelenetz, Paolo Abada, Anthony R Mato, Nirav N Shah

Förderung

  • NCI NIH HHS

Zitieren

APA

Wang, M. L., Jurczak, W., Zinzani, P. L., Eyre, T. A., Cheah, C. Y., Ujjani, C. S., Koh, Y., Izutsu, K., Gerson, J. N., Flinn, I., Tessoulin, B., Alencar, A. J., Ma, S., Lewis, D., Lech-Maranda, E., Rhodes, J., Patel, K., Maddocks, K., Lamanna, N., …, & Shah, N. N. (2023). Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma. Journal of Clinical Oncology, 41(24), 3988-3997. https://doi.org/10.1200/jco.23.00562

Vancouver

Wang ML, Jurczak W, Zinzani PL, Eyre TA, Cheah CY, Ujjani CS, et al. Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma. Journal of Clinical Oncology. 2023;41(24):3988-3997. doi:10.1200/jco.23.00562

BibTeX
@article{Wang2023,
  author = {Wang, Michael L and Jurczak, Wojciech and Zinzani, Pier Luigi and Eyre, Toby A and Cheah, Chan Y and Ujjani, Chaitra S and Koh, Youngil and Izutsu, Koji and Gerson, James N and Flinn, Ian and Tessoulin, Benoit and Alencar, Alvaro J and Ma, Shuo and Lewis, David and Lech-Maranda, Ewa and Rhodes, Joanna and Patel, Krish and Maddocks, Kami and Lamanna, Nicole and Wang, Yucai and Tam, Constantine S and Munir, Talha and Nagai, Hirokazu and Hernandez-Ilizaliturri, Francisco and Kumar, Anita and Fenske, Timothy S and Seymour, John F and Zelenetz, Andrew D and Nair, Binoj and Tsai, Donald E and Balbas, Minna and Walgren, Richard A and Abada, Paolo and Wang, Chunxiao and Zhao, Junjie and Mato, Anthony R and Shah, Nirav N},
  title = {Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma},
  journal = {Journal of Clinical Oncology},
  year = {2023},
  volume = {41},
  number = {24},
  pages = {3988--3997},
  doi = {10.1200/jco.23.00562}
}
Kostenlos starten →